File ID,Petition File Name,Date of Petition,Was_Withdrawn,Document Type,Submitter,Submitter Type,Petition Cited Statutes or Regulations,FDA Action Commented On,Requested Action,Justification for Request,Interim Response Date,Final Decision,Last Response Date,Count of Interim,Responding FDA Center (of Final Decision),Responses Cited Statutes or Regulations,Justification for Interim Response,Justification for Final Response,Cleaned Final Decision,Year,Response Time (Days)
fda-2017-p-0052,FDA-2017-P-0052-0001_Citizen_Petition_from_Donor_Sibling_Registry.pdf,2017-01-01,False,original petition,Donor Sibling Registry,advocacy/academic,"- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.30 (categorical environmental exemption claimed)","Lack of regulation and oversight in the sperm donation/cryobank industry. Specifically, minimal FDA-mandated medical testing for sperm and egg donors and the broader absence of national regulatory oversight.","The petitioner asks the FDA Commissioner to investigate the current state of the sperm donation industry and develop appropriate regulations and oversight mechanisms. Key regulatory proposals include:
• Standardized and expanded pre-conception testing
• Mandated full genome sequencing
• Required medical, genetic, and social updates
• Electronic health record-keeping
• Ban on anonymous donation
• Centralized databank tracking donors, recipients, and births","The petition outlines that the U.S. cryobank industry is a multibillion-dollar, largely unregulated sector, leading to:
• Inconsistent medical/genetic screening standards
• Insufficient communication of critical health data
• Donor fraud and identity falsification
• Psychological and health risks to donor-conceived children
• Inadequate recordkeeping, enabling excessive offspring numbers per donor and risk of consanguinity.
They reference case studies, lawsuits (e.g., Collins v. Xytex), surveys, and failures in current practices as rationale for regulatory reform",,,2025-10-15,0.0,,,,,no decision,2017,3209.0
fda-2017-p-0137,FDA-2017-P-0137-0001_Citizen_Petition_from_Macleods_Pharmaceuticals_Lim.pdf,2017-01-09,True,original petition,Macleods Pharmaceuticals Limited,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.20, 10.30, 314.93 (citizen petition and ANDA suitability petition provisions)
- 21 C.F.R. § 25.31(a) and 25.15(d) (categorical exclusion from environmental assessment)","The petition comments on the absence of a currently available Reference Listed Drug (RLD) for Pyrazinamide Tablets 500 mg, and requests designation of an alternative RLD to support ANDA filing","Macleods requests FDA to designate the approved generic product ANDA #A081319 (Pyrazinamide Tablets 500 mg by Akorn Inc.) as the RLD, due to the unavailability of the existing RLD (ANDA #A080157 by Dava Pharmaceuticals)
","- The current RLD (Pyrazinamide 500 mg by Dava) is not available in the U.S. market, even though not marked as discontinued in the Orange Book.
- Akorn’s product (ANDA #A081319) is the only approved and marketed generic for this dosage form and strength, and is the market leader.
- According to FDA’s policy outlined in the 1992 ANDA regulations, the market leader may be designated as RLD when the original is unavailable.
- Petition includes IMS market data and Orange Book listings as supporting evidence",7/7/2017,,2025-10-15,1.0,,,"The FDA stated that the petition ""raises complex issues requiring extensive review and analysis by Agency officials,"" which has delayed a final decision 
",,no decision,2017,3201.0
fda-2017-p-0176,FDA-2017-P-0176-0001_Citizen_Petition_from_American_Herbal_Products_Ass.pdf,2017-01-09,False,original petition,"Kleinfeld, Kaplan and Becker, LLP",law/consulting,"- 21 C.F.R. § 10.30 (Citizen Petition procedures)
- 21 C.F.R. § 101.4(h) (Labeling of dietary supplements)
- 68 Fed. Reg. 51738 (August 28, 2003) – Proposed amendment to 21 C.F.R. § 101.4(h)
- 21 C.F.R. § 25.30 (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact statement provisions)","The FDA’s proposed amendment to 21 C.F.R. § 101.4(h), specifically the 2003 proposal to replace the incorporated references (1992 edition of Herbs of Commerce and 1994 edition of International Code of Botanical Nomenclature) with their 2000 editions.","AHPA requests that FDA:
1. Withdraw the proposed rule published at 68 Fed. Reg. 51738.
2. Issue an Advance Notice of Proposed Rulemaking (ANPRM) to revise 21 C.F.R. § 101.4(h), suggesting that botanical names on supplement labels be consistent with the Herbs of Commerce, 2nd edition (2000), or other appropriate authoritative references","- The current reference (Herbs of Commerce, 1st ed., 1992) is outdated.
- The 2nd edition (2000) includes standardized common names for ~1,500 more botanicals and updates ~140 names from the 1st edition.
- Plant taxonomy evolves, and new references reflect more accurate nomenclature.
- There is a need for clarity and consistency in naming botanical dietary ingredients to reflect modern commerce and ensure regulatory compliance",2/2/2018,,2025-10-15,1.0,,,"The FDA stated the petition is under active evaluation, but decision-making has been delayed due to competing agency priorities ",,no decision,2017,3201.0
fda-2017-p-0398,FDA-2017-P-0398-0001_Citizen_Petition_from_Florek___Endres_PLLC.pdf,2017-01-18,True,original petition,Florek & Endres PLLC,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. §§ 10.20, 10.30, and 314.93 (petition procedures and ANDA suitability petitions)
- 21 C.F.R. § 25.31 (categorical exclusion from environmental assessment)
- 21 C.F.R. § 10.30(b) (economic impact information on request)","The petition addresses the FDA’s determination on whether a new strength (24 mg) of Hydromorphone HCl extended-release tablets is suitable for submission under an ANDA, referencing the approved reference listed drug (RLD) EXALGO®","The petitioner requests that the FDA declare the 24 mg strength of Hydromorphone HCl extended-release tablets suitable for ANDA submission, citing the EXALGO® product line as reference","- The 24 mg strength would fill a dosing gap between existing 16 mg and 32 mg EXALGO® strengths, reducing the need to combine tablets and mitigating risks of dosage errors.
- The dosage is consistent with EXALGO®'s labeled titration recommendations and would aid safer opioid conversion and titration.
- The proposed strength exhibits similar dissolution and pharmacokinetic properties to the RLD.
- The dosage is expected to be used and prescribed safely, with potentially lower abuse liability than the 32 mg strength.
- It does not raise questions of safety or effectiveness since the formulation and route of administration remain consistent with the RLD",,,2025-10-15,0.0,,,,,no decision,2017,3192.0
fda-2017-p-0508,FDA-2017-P-0508-0001_Citizen_Petition_from_the_Union_of_Concerned_Scien.pdf,2017-01-25,False,original petition,"Union of Concerned Scientists, Center for Science and Democracy",advocacy/academic,"- 5 U.S.C. § 553(e)
- 21 C.F.R. § 10.25
- 21 C.F.R. § 10.30
- 21 C.F.R. § 101.13
- 21 C.F.R. § 101.14
- 21 C.F.R. § 25.30(h)
- 21 C.F.R. § 10.30(b)(3)
- 21 C.F.R. § 101.65
- 21 U.S.C. § 343
- Sections 201(n), 403A, and 701(a) of the FD&C Act
- Nutrition Labeling and Education Act of 1990","- Current FDA regulations allowing health and nutrient content claims on foods with high added sugar content
- Draft guidance on redefining the “healthy” nutrient content claim","- Amend 21 C.F.R. §§ 101.13 and 101.14 to include a disqualifying nutrient level for added sugars
- Prevent foods with added sugars above the threshold from making health or nutrient content claims","- Scientific evidence links excessive added sugar to chronic diseases (e.g., type 2 diabetes, CVD, obesity)
- Added sugar now has a defined DRV (25g for ages 1–3, 50g for 4+)
- Precedent exists for disqualifying levels for fat, sodium, etc.
- Prevent misleading claims that make sugar-rich foods appear healthy, especially for children
- Supported by over 30,000 individuals nationwide",7/17/2017,,2025-10-15,1.0,,,The FDA stated that it has not completed review of the petition due to other agency priorities and limited availability of resources. The Agency committed to notify the petitioner once a decision is reached ,,no decision,2017,3185.0
fda-2017-p-0757,FDA-2017-P-0757-0001_Citizen_Petition_from_Beck___Thomas.pdf,2017-02-10,True,original petition,"Beck & Thomas, P.C.",law/consulting,"- Sections 505 and 505-1 of the FDCA (21 U.S.C. §§ 355 and 355-1)
- 21 C.F.R. Parts 10 and 314
- 21 C.F.R. § 25.31(a) (Environmental impact exclusion)
- ICH Q3D Elemental Impurities Guidance (Sept. 2015)
- USP Chapters <232> and <233>
- FDA’s Draft Guidance on Elemental Impurities (June 2016)
- 505(o) Letters under FDCA
- APA (Administrative Procedure Act)","The petition comments on the review and approval process of NDAs and ANDAs for potassium chloride oral drug products. It specifically challenges FDA's handling of applications that do not include completed risk assessments for elemental impurities, urging refusal to receive or approve such filings
","- Refuse to file or receive any NDA/ANDA for potassium chloride oral drug products without completed risk assessments and controls for elemental impurities (lead, arsenic, cadmium, mercury, chromium, copper, selenium, manganese, zinc, and other process metals).
- Do not approve any pending NDAs or ANDAs until such documentation is provided","- FDA has already made a safety determination about potential elemental impurities in potassium chloride products.
- FDA has issued 505(o) letters to NDA holders requiring risk assessments for specific metals.
- The petition cites guidance documents and USP standards enforcing control of such impurities by January 1, 2018.
- These products are widely used and may pose toxicity risks if uncontrolled",,,2025-10-15,0.0,,,,,no decision,2017,3169.0
fda-2017-p-0863,FDA-2017-P-0863-0001_Citizen_Petition_from_Fresenius_Kabi_USA__LLC_2.pdf,2017-02-08,True,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"- 21 C.F.R. §§ 10.20, 10.30, and 314.93
- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.31(a) (Environmental Impact)","The suitability for submission of an Abbreviated New Drug Application (ANDA) for Sodium Chloride 23.4% Injection, USP, in 100 mL and 200 mL pharmacy bulk package (PBP) vials. The reference listed drug (RLD) is a 30 mL vial of the same formulation that was discontinued but not withdrawn for safety or efficacy reasons.
","The petitioner requests that the FDA declare the 100 mL and 200 mL PBP vials of Sodium Chloride 23.4% Injection, USP to be suitable for ANDA submission, as an increase in total drug content from the previously approved 30 mL single-dose vial
","- The proposed product is identical in concentration (23.4%), indications, route of administration, and composition to the approved RLD, differing only in volume.
- Larger vials (100 mL, 200 mL) would reduce waste, improve convenience for hospitals and infusion centers, and potentially reduce costs.
- The packaging aligns with USP <797> and <1> requirements for pharmacy bulk packaging.
- Labeling changes will address aseptic handling and single-use time limits (e.g., 24 hours).
- There are no new safety or effectiveness issues raised by this petition
",,,2025-10-15,0.0,,,,,no decision,2017,3171.0
fda-2017-p-1298,FDA-2017-P-1298-0001_Citizen_Petition_from_The_Good_Food_Institute.pdf,2017-03-02,False,original petition,The Good Food Institute (GFI),advocacy/academic,"- 21 C.F.R. § 10.30 (Citizen petition)
- 5 U.S.C. § 553(e) (APA right to petition for rulemaking)
- 21 U.S.C. § 343(a)(1) (FDCA: misbranding due to false or misleading labeling)
- 21 C.F.R. § 101.3(b) (standard of identity for common food names)
- 21 U.S.C. § 321(g) (definition of ""drug"" under FDCA)","GFI comments on recent suggestions that plant-based products should be restricted from using terms like “milk,” “meat,” and “eggs” on their labels. These suggestions imply that plant-based products using such terms are misleading or violate standards of identity.","GFI requests that FDA:
1. Issue a regulation or guidance recognizing that compound terms like “soy milk,” “almond milk,” “vegan cheese,” and “plant-based meat” are not misleading when the plant source is clear.
2. Reaffirm existing labeling rules allowing these terms under current FDA law.","- Terms like “soy milk” and “vegan cheese” have been used for decades and are well understood by consumers.
- Plant-based labeling provides accurate information and facilitates consumer choice.
- Restricting these terms would violate the First Amendment and contradict consumer understanding.
- There is no evidence of consumer confusion over these terms.
- The FDA’s past enforcement policy has tolerated these labels, and no formal standard excludes plant-based variants from common usage names.",8/29/2017,,2025-10-15,1.0,,,"- The petition requested FDA to issue regulations clarifying how foods may be named by reference to the names of other foods.
- FDA indicated that it had not yet reached a decision due to competing priorities within the agency.
- They committed to completing review and considering amendments as warranted within the context of other program priorities
",,no decision,2017,3149.0
fda-2017-p-1359,FDA-2017-P-1359-0001_Citizen_Petition_from_Pharmaceutical__Manufacturin.pdf,2017-03-06,False,original petition,"Pharmaceutical Manufacturing Research Services, Inc. (PMRS)",industry/corporation,"- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31
- Section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)","The FDA’s approval and labeling of:
- OxyContin’s indication for chronic pain
- All extended-release opioids indicated for chronic pain
- All immediate-release opioids used for chronic pain","PMRS requests that the FDA:
(i) Revoke OxyContin's approval for chronic pain
(ii) Revoke approval of all ER opioids for chronic pain
(iii) Revoke IR opioid labeling supporting chronic pain use","- FDA approved chronic pain indication for OxyContin without substantial evidence
- Misuse, addiction, and overdose risks have increased
- Chronic pain indication contradicts scientific data and public health findings
- OxyContin was originally approved only for acute use; later changes led to widespread abuse
- The change contributed to the opioid epidemic; over 200,000 deaths cited",8/31/2017,,2025-10-15,1.0,,,"- The petition requested the FDA to revoke certain labeling approvals related to both extended-release and immediate-release opioid products, specifically seeking revocation of:
1. OxyContin’s chronic use labeling
2. ER opioids for chronic pain
3. IR opioids for chronic pain
4. Replace IR labeling with indications for acute pain only.
- FDA explained that the petition raised significant and complex issues requiring extensive internal review and analysis by agency officials. Hence, an interim response was issued pending further evaluation
",,no decision,2017,3145.0
fda-2017-p-1391,FDA-2017-P-1391-0001_Citizen_Petition_from_Epstein_Becker___Green_P_C_.pdf,2017-03-03,False,original petition,"Epstein Becker & Green, P.C.",law/consulting,"- 21 C.F.R. § 10.30 (Citizen Petition)
- 21 C.F.R. § 10.75 (Internal agency review procedures)
- 21 C.F.R. § 3.8 (Letter of designation rules)
- 21 C.F.R. § 25.30 (Environmental impact exclusion)
- 5 U.S.C. §§ 555(b), 706(1), 706(2)(A) (Administrative Procedure Act)
- 21 U.S.C. § 353(g) (FDCA designation provisions)
- 21st Century Cures Act, Sec. 3038","The petition comments on the lack of a regulatory timeline for appeals of FDA’s letter of designation decisions made by the Office of Combination Products under 21 C.F.R. § 3.8.
","- Amend 21 C.F.R. § 3.8 to include a new subsection (d): FDA must complete review of appeals under 21 C.F.R. § 10.75 within 60 calendar days.
- Require all pending appeals submitted prior to October 1, 2015, to be resolved by March 9, 2017","- Significant delays (some over 17 months) in decision-making due to lack of timelines.
- Delays violate the Administrative Procedure Act by allowing “arbitrary” and untimely decisions.
- Delays hinder correction of errors in designation decisions and delay compliance with the 21st Century Cures Act.
- Innovators lose patent time and are forced to accept erroneous designations.
- Most importantly, delays harm public health by slowing patient access to new therapies",,,2025-10-15,0.0,,,,,no decision,2017,3148.0
fda-2017-p-1460,FDA-2017-P-1460-0001_Citizen_Petition_from_Covington___Burling_LLP.pdf,2017-03-09,True,original petition,Covington & Burling LLP,law/consulting,"- 21 C.F.R. §§ 10.20 and 10.30 (Citizen Petition procedures)
- 21 C.F.R. §§ 25.30 and 25.31 (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact)
- Section 505(j) of the FD&C Act","The petition addresses the designation of reference listed drugs (RLDs) in the FDA’s Orange Book, specifically advocating for RASUVO (methotrexate injection) to be listed as a second RLD alongside OTREXUP for subcutaneous methotrexate solution. 
","The petitioner requests that the FDA amend the Orange Book to designate RASUVO (NDA 205776) as a second reference listed drug (RLD) for methotrexate (solution) injection for subcutaneous use, in strengths ranging from 7.5 mg to 30 mg at 50 mg/mL concentration. 
","- The Orange Book currently lists OTREXUP (NDA 204824) as the sole RLD, with fixed volume (0.4 mL) and varying concentration per strength.
- RASUVO uses a fixed concentration (50 mg/mL) and varying volumes to achieve strengths, but the total drug content per dose is equivalent.
- RASUVO includes additional strengths (27.5 mg, 30 mg) not available in OTREXUP.
- A prior FDA petition (FDA-2014-P-0318) was denied when Antares Pharma tried to block non-OTREXUP products, with FDA affirming that products like RASUVO may differ in acceptable ways.
- This designation would support ANDAs for methotrexate products matching RASUVO’s formulation. ",8/31/2017,,2025-10-15,1.0,,,"- The citizen petition requested that FDA designate methotrexate solution injection for subcutaneous use (NDA 205776, Medac Pharma Inc.) in specific strengths as an additional reference listed drug in the Orange Book.
- FDA stated it could not yet reach a decision due to other agency priorities and limited resources, issuing this letter in compliance with federal regulations",,no decision,2017,3142.0
fda-2017-p-1463,FDA-2017-P-1463-0001_Citizen_Petition_from_Tate___Lyle_Ingredients_Amer.pdf,2017-03-08,False,original petition,Tate & Lyle Ingredients Americas LLC,industry/corporation,"- 21 C.F.R. § 10.30 (Citizen Petition provision)
- 21 C.F.R. § 101.9(c)(1)(i) (caloric value labeling regulation)
- 21 C.F.R. § 25.31 (Environmental impact exclusion)","The petition comments on FDA's regulation of caloric values listed on nutrition labels, specifically requesting a rulemaking amendment to 21 C.F.R. § 101.9(c)(1)(i) to define a new caloric value for Allulose.
","The petitioner requests that FDA:
1. Amend 21 C.F.R. § 101.9(c)(1)(i) to specify that Allulose contributes 0.2 kcal/g and list it under a new subsection (G).
2. Set the amendment’s effective date 30 days after Federal Register publication.
3. Set the compliance date two years post-publication (three years for small manufacturers). ","- Scientific evidence, including a radiotracer metabolism study conducted by Tate & Lyle, demonstrated that Allulose is absorbed but not metabolized, and is excreted largely intact, contributing 0.2 kcal/g or less.
- The Iida et al. (2010) study estimated the caloric value between 0.20–0.39 kcal/g, supporting Tate & Lyle's position.
- A rigorous human 14C-labeled radiotracer study showed over 80% urinary recovery, minimal fecal excretion, and negligible 14CO2 in breath, confirming no significant metabolism.
- Animal studies (e.g., Matsuo 2002) supported these findings, showing Allulose’s energy deposition efficiency was only 0.3% of sucrose.
- The petitioner emphasizes that labeling Allulose at 0.2 kcal/g reflects the most scientifically accurate and conservative value based on current data. ",,,2025-10-15,0.0,,,,,no decision,2017,3143.0
fda-2017-p-1495,FDA-2017-P-1495-0001_Citizen_Petition_from_Sandoz_Inc.pdf,2017-03-10,True,original petition,Sandoz Inc.,industry/corporation,"- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.3
- FDC Act § 505(j)
- FDC Act §§ 505(e)(1)–(5) and (j)(6)
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b) ","The petition comments on the designation of reference standards in the Orange Book, specifically requesting that the FDA update the Orange Book to designate ANDA 065117 for Amoxicillin and Clavulanate Potassium Tablets USP, 500MG / 125MG as a reference standard, instead of the currently designated RLD (NDA 050564 - “AUGMENTIN” 500 by Dr. Reddy’s Labs). ","FDA is requested to: Designate ANDA 065117 as the reference standard for Amoxicillin and Clavulanate Potassium Tablets USP, 500MG / 125MG BASE in the Orange Book. 
","- The current RLD (NDA 050564) was unavailable for purchase in the U.S. market, creating a barrier to bioequivalence testing.
- Sandoz’s ANDA 065117 is the market leader in terms of units sold (as shown in the IMS sales data table on page 2).
- FDA guidance allows for new reference standard designation when distribution of the current standard is too limited to enable testing.
- Sandoz argues that these factors justify its ANDA product being listed as the reference standard. ",,,2025-10-15,0.0,,,,,no decision,2017,3141.0
fda-2017-p-1911,FDA-2017-P-1911-0001_Citizen_Petition_from_Kleinfeld__Kaplan_and_Becker.pdf,2017-03-27,True,original petition,"Kleinfeld, Kaplan & Becker, LLP",law/consulting,"• 21 C.F.R. § 10.30 (Citizen‑petition rule) • 21 C.F.R. Parts 314 & 320 • FDCA §§ 505(b) & 505(j) (21 U.S.C. §§ 355(b), 355(j)) • FDCA § 505(b)(2) • 21 C.F.R. § 314.94(a)(9)(v) • 21 C.F.R. § 314.127(a)(8)(ii)(A) • 21 U.S.C. § 355(j)(4)(H) • 21 C.F.R. §§ 314.94(a)(8)(iv), 314.127(a)(7) • 21 C.F.R. § 25.31 • 16 C.F.R. Part 1700 • 21 C.F.R. § 3.2(e)(1)–(2)","FDA’s review & potential approval of any ANDA (505(j)) or 505(b)(2) NDA that references BUTRANS® as the reference‑listed drug.        
","Require that every such follow‑on application:
1. Include toxicology & extractable‑leachable data adequate to show safety equivalence to BUTRANS®; and
2. Provide a patch‑disposal system demonstrated, via comparative extraction, senior‑use and child‑resistance testing, to perform at least as safely and effectively as the BUTRANS Patch‑Disposal Unit.","Safety concerns: Differences in formulation or packaging can introduce toxicological risks that require data beyond standard bioequivalence testing; lack of a robust disposal system increases accidental exposure and abuse potential. Ensuring equivalent toxicology data and a proven disposal device is therefore necessary for follow‑on products to be “as safe as BUTRANS.”	
",,,2025-10-15,0.0,,,,,no decision,2017,3124.0
fda-2017-p-2131,FDA-2017-P-2131-0001_Citizen_Petition_from_Menn_Law_Firm_LTD.pdf,2017-04-04,True,original petition,"Menn Law Firm, Ltd.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 C.F.R. §§ 10.20, 10.30, 314.161, 25.31(a), 25.15(d)","Reference Standard designation for Aminocaproic acid in the FDA Orange Book. Specifically, the petitioner is requesting FDA to replace the current Reference Standard (AMICAR 1g Tablets) with the 500mg strength.
","Request for FDA to designate AMICAR (Aminocaproic acid) 500mg Tablets (Application No. NDA 015197) as the Reference Standard (RS), replacing the unavailable 1g tablet strength
","- The current RS, AMICAR 1g tablets, is not actively marketed or available in the U.S. market.
- FDA guidance requires bioequivalence testing with the RS, but ANDA sponsors cannot obtain the 1g tablets.
- The 500mg version is actively marketed under the same NDA and should be designated as RS to enable product development and ANDA submission",,,2025-10-15,0.0,,,,,no decision,2017,3116.0
fda-2017-p-2164,FDA-2017-P-2164-0001_Citizen_Petition_from_Steptoe___Johnson__LLP__Nati.pdf,2017-04-05,False,original petition,Steptoe & Johnson LLP,law/consulting,"- 21 C.F.R. §§ 10.25, 10.30, 10.33, 10.35
- 21 U.S.C. § 343(q)(5)(H)
- 5 U.S.C. § 553(b)(B), § 706
- Administrative Procedures Act (APA)
- Executive Order 13771
- Executive Order 13777 ","The Final Rule on Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments (79 Fed. Reg. 71156, Dec. 1, 2014) 
","- Stay the effective date of the Final Rule (under 21 C.F.R. § 10.35(b))
- Reconsider the Final Rule and commence a new rulemaking process under section 4205 of the ACA (21 U.S.C. § 343(q)(5)(H))","- Impossibility of Compliance: Petitioners cite ambiguity in definitions (e.g., what constitutes a ""menu""), unaddressed compliance guidance, and unfeasible implementation timelines.
- Underestimated Costs: FDA underestimated compliance costs for non-restaurant retailers, which are in the hundreds of millions to billions of dollars.
- Overreach and Improper Scope: The Final Rule extends beyond what Congress intended by applying to businesses not “similar” to restaurants.
- First Amendment Concerns: The rule mandates potentially misleading commercial speech and fails to directly advance a substantial government interest.
- Inconsistency with Federal Policy: The Final Rule conflicts with executive directives aimed at reducing regulatory burdens on businesses. ",6/29/2017,,2025-10-15,1.0,,,"- The petition requested a stay and reconsideration of the FDA’s final rule on “Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments.”
- FDA explained that they were still reviewing the petition and that they had already extended the compliance date for the rule to May 7, 2018 (as published in the Federal Register on May 4, 2017, 82 Fed. Reg. 20825).
- FDA also noted they were extending the comment period on the interim final rule by another 30 days and encouraged further comments
",,no decision,2017,3115.0
fda-2017-p-2231,FDA-2017-P-2231-0001_Citizen_Petition_from_Qilu_Pharma__Inc__as_the_US_.pdf,2017-04-07,True,original petition,"Qilu Pharma, Inc.",industry/corporation,"- 21 CFR § 10.25(a) – General procedures for submitting petitions
- 21 CFR § 10.30 – Citizen petition requirements
- 21 CFR § 25.31(a) – Environmental impact categorical exclusion","FDA’s current designation of only one RLD for Carboplatin Injection (application No. N020452, by CordenPharma), which is listed in the Discontinued Section of the Orange Book
",Request to designate Pharmachemie BV’s Carboplatin Injection (A077269) as an additional RLD to support Qilu’s ANDA submission for identical dosage strengths,"- Existing RLD (CordenPharma) is discontinued, though not withdrawn for safety or effectiveness reasons.
- Pharmachemie BV’s product matches dosage strengths (50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, 600 mg/60 mL at 10 mg/mL).
- Designation would facilitate Qilu’s ANDA filing for identical strengths, aiding generic market entry",,,2025-10-15,0.0,,,,,no decision,2017,3113.0
fda-2017-p-2245,FDA-2017-P-2245-0001_Citizen_Petiton_from_Fresenius_Kabi_USA__LLC.pdf,2017-04-07,True,original petition,"Fresenius Kabi USA, LLC",industry/corporation,"- 21 C.F.R. § 10.20 – Submission of petitions
- 21 C.F.R. § 10.30 – Citizen petition procedures
- 21 C.F.R. § 314.3(b) – Definitions including reference listed drug
- Section 505(j) of the FD&C Act – ANDA provisions
- 21 C.F.R. § 10.31(a) – Environmental impact exemption","The absence of an FDA designation of a Reference Listed Drug (RLD) for Lactated Ringer’s and Dextrose 5% injections, despite several approved NDAs. The petitioner comments on the need for such designation to allow ANDA referencing","FDA should designate Baxter Healthcare’s NDA 016679 (Lactated Ringer’s and 5% Dextrose injection) as the Reference Listed Drug (RLD)
","- FDA’s Orange Book lists three NDAs for the formulation but none are currently designated as RLDs.
- ANDA applicants cannot proceed without an RLD.
- Designating NDA 016679 (Baxter) as the RLD would support development of multisource ANDAs for this formulation.
- The petitioner claims a categorical exclusion from environmental impact reporting and does not include economic impact due to non-applicability",10/4/2017,,2025-10-15,1.0,,,"The FDA cited the need to address other Agency priorities and stated that due to numerous demands on resources, a final response could not yet be issued. An interim response was provided in compliance with regulatory requirements
",,no decision,2017,3113.0
fda-2017-p-2460,FDA-2017-P-2460-0001_Citizen_Petition_from_AuroMedics_Pharma_LLC__Aurob.pdf,2017-04-18,True,original petition,AuroMedics Pharma LLC,industry/corporation,"- 21 C.F.R. § 10.30 – Citizen Petition process
- 21 C.F.R. § 10.20 – Submission of documents
- 21 C.F.R. § 10.25(a) – Right to petition
- 21 C.F.R. § 314.122 – Discontinued drugs
- 21 C.F.R. § 314.161 – Determination on safety/effectiveness of discontinued drugs
- 21 C.F.R. § 25.31(a) – Environmental impact exclusion","The discontinuation of NDA 019038 for CALAN® (verapamil hydrochloride) Injection, 2.5 mg/mL by GD Searle LLC. Petitioner seeks clarification that it was not withdrawn for safety or efficacy reasons
","- FDA should determine that NDA 019038 was not discontinued for safety or efficacy reasons.
- FDA should designate NDA 019038 as a Reference Listed Drug (RLD) to allow submission of an ANDA by Aurobindo","- NDA 019038 was approved on March 30, 1984, and has since been discontinued.
- There is no RLD currently designated for Verapamil Hydrochloride Injection in the Orange Book.
- Aurobindo intends to develop a generic version matching the same strengths, dosage form, active/inactive ingredients, and indications as the original formulation (see side-by-side comparison table on page 2).
- The formulation is medically identical and supports an ANDA submission if FDA grants the RLD designation",,,2025-10-15,0.0,,,,,no decision,2017,3102.0
fda-2017-p-2661,FDA-2017-P-2661-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2017-04-27,True,original petition,Foley & Lardner LLP,law/consulting,"- 21 C.F.R. § 10.30 – Citizen petition process
- 21 C.F.R. § 314.93 – Petition to request change in dosage form
- 21 C.F.R. § 314.94 – Requirements for Abbreviated New Drug Application (ANDA)
- 21 C.F.R. § 25.1(g) – Environmental impact exclusion
- 21 C.F.R. § 10.30(b) – Economic impact statement provision
- Section 505(j)(2)(C) of the FD&C Act","Requesting that the FDA allow submission of an ANDA for Empagliflozin Capsules (10 mg and 25 mg) as an alternative dosage form to the Reference Listed Drug (RLD), Jardiance Tablets (10 mg and 25 mg)
","FDA is requested to declare that:
1. Empagliflozin Capsules (10 mg and 25 mg) are suitable for submission as an ANDA.
2. The reference product is Jardiance Tablets (10 mg and 25 mg)
","- The proposed product has same active ingredient, strength, and route of administration as the RLD, differing only in dosage form (capsule vs. tablet).
- Intended to provide an alternative dosage form for patients with difficulty swallowing tablets.
- Labeling will be identical to the RLD except for manufacturer details and inactive ingredients.
- Pediatric study submission is deferred until after the RLD sponsor completes its requirements (post-August 2019).
- Environmental and economic reports are not required per FDA regulations",,,2025-10-15,0.0,,,,,no decision,2017,3093.0
fda-2017-p-2674,FDA-2017-P-2674-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2017-04-27,True,original petition,Foley & Lardner LLP,law/consulting,"- 21 C.F.R. § 10.30 – Citizen petition process
- 21 C.F.R. § 314.93 – Petition to request a change in dosage form
- Section 505(j)(2)(C) of the FD&C Act – Suitability petitions for ANDAs
- 21 C.F.R. § 314.94 – ANDA content and format
- 21 C.F.R. § 25.1(g) – Environmental impact exclusion
- 21 C.F.R. § 10.30(b) – Economic impact statement provision","Requesting FDA approval for a suitability petition to allow submission of an ANDA for Empagliflozin and Linagliptin Capsules (10 mg/5 mg and 25 mg/5 mg), which differ in dosage form from the RLD Glyxambi (tablets)
","FDA is requested to declare that:
1. Empagliflozin and Linagliptin Capsules (10 mg/5 mg and 25 mg/5 mg) are suitable for submission as an ANDA under 21 C.F.R. § 314.94.
2. The RLD is Glyxambi Tablets (10 mg/5 mg, 25 mg/5 mg)
","- The only difference from the RLD is dosage form (capsule vs. tablet); active ingredients, strength, and route of administration are the same.
- Labeling will remain consistent with RLD, aside from manufacturer and excipient differences.
- The FDA has previously approved similar petitions to provide alternative forms for patients who have difficulty swallowing tablets.
- Pediatric study requirements for the RLD were waived by FDA.
- The petition qualifies for environmental and economic impact exclusions",,,2025-10-15,0.0,,,,,no decision,2017,3093.0
fda-2017-p-2869,FDA-2017-P-2869-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,2017-05-05,True,original petition,"Lachman Consultant Services, Inc.",industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. § 10.30 – Citizen petitions
- 21 C.F.R. § 314.93 – Petition to request change in dosage form
- 21 C.F.R. § 25.31 – Environmental impact categorical exclusion","The petition seeks FDA’s determination that Glycopyrrolate Orally Disintegrating Tablets (ODT) in 1 mg, 1.5 mg, and 2 mg strengths are suitable for submission as an Abbreviated New Drug Application (ANDA). The reference listed drug (RLD) is Robinul Forte (glycopyrrolate) Tablets by Casper Pharma","Request FDA to:
- Declare that Glycopyrrolate ODT (1 mg, 1.5 mg, 2 mg) is suitable for ANDA submission as a change in dosage form from the RLD.
- Grant a full waiver from pediatric study requirements under PREA","- The change is limited to dosage form; no change in strength, indication, or labeling (except administration method).
- Provides benefit for patients with dysphagia or difficulty swallowing tablets.
- Labeling will mirror RLD except for administration instructions.
- Peptic ulcer is rare in pediatric patients, and glycopyrrolate is unlikely to be used in significant numbers in this group; therefore, waiver from pediatric studies is justified.
- Environmental impact is minimal, qualifying for categorical exclusion",,,2025-10-15,0.0,,,,,no decision,2017,3085.0
fda-2017-p-3201,FDA-2017-P-3201-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2017-05-19,True,original petition,Foley & Lardner LLP,law/consulting,"- 21 C.F.R. § 10.30 – Citizen petition procedure
- 21 C.F.R. § 25.1(g) – Environmental impact exemption
- 21 C.F.R. § 10.30(b) – Economic impact statement provision","The absence of designation of the following drugs as Reference Listed Drugs (RLDs) in the FDA Orange Book, despite their approval status:
- NDA 17714: Technetium Tc-99m Pentetate Kit (AN-DTPA) by Jubilant Draximage, Inc.
- NDA 18511: Technetium Tc-99m Pentetate Kit (DTPA) by Draximage, Inc.",The petitioner requests the FDA to designate both NDA 17714 and NDA 18511 products as Reference Listed Drugs (RLDs) in the Orange Book so that they can be referenced in Abbreviated New Drug Applications (ANDAs),"- Both NDAs are listed in the active section of the FDA’s Orange Book but neither is designated as an RLD, which is necessary for ANDA filings.
- The petitioner finds no justification for the omission and requests correction to facilitate the submission of ANDAs referencing these products",,,2025-10-15,0.0,,,,,no decision,2017,3071.0
fda-2017-p-3202,FDA-2017-P-3202-0001_Citizen_Petition_from_Foley___Lardner_LLP.pdf,2017-05-19,True,original petition,Foley & Lardner LLP,law/consulting,"- 21 C.F.R. § 10.30 – Citizen petition procedure
- 21 C.F.R. § 25.1(g) – Environmental impact exclusion
- 21 C.F.R. § 10.30(b) – Economic impact statement requirements","The lack of designation of Technetium Tc-99m Bicisate Kit (NEUROLITE®, NDA 20256) as a Reference Listed Drug (RLD) in the FDA’s Orange Book. Although the product is approved and listed, it is not designated as an RLD, which prevents ANDA applicants from referencing it","The petitioner requests that the FDA designate NEUROLITE® (Technetium Tc-99m Bicisate Kit, NDA 20256) as the Reference Listed Drug in the Orange Book, enabling filing of Abbreviated New Drug Applications (ANDAs) referencing it","- There is an approved NDA for NEUROLITE®, but it is not currently designated as an RLD in the Orange Book.
- ANDA applicants require an RLD designation to reference a product in their submissions.
- The absence of an RLD designation for NEUROLITE is unexplained and restricts generic competition.
- The petitioner asserts that there is no reason not to designate the product as an RLD, given its approved status and listing in the Orange Book",,,2025-10-15,0.0,,,,,no decision,2017,3071.0
fda-2017-p-3251,FDA-2017-P-3251-0001_Citizen_Petition_from_Petitioner__Redacted.pdf,,False,original petition,Anonymous (redacted),other,"- 35 U.S.C. § 156 – Patent Term Restoration Act (used to request denial or limitation of a patent extension)
- References the term “due diligence” as defined in the statute for regulatory review periods ","The petition responds to Genzyme’s application for patent term extension of the drug Cerdelga under 35 U.S.C. § 156, related to regulatory review periods. Specifically, it asks the FDA to deny or limit Genzyme’s requested extension due to alleged lack of due diligence during the drug development and approval process 
","The petitioner requests the FDA to:
1. Conduct a due diligence investigation into Genzyme’s development of Cerdelga.
2. Determine that Genzyme failed to act with due diligence during the regulatory review period (2002 to approval).
3. Deny or limit the patent extension Genzyme seeks for Cerdelga.
4. Recommend to the USPTO that the extension be denied, rejected, or limited ","The petition argues that:
- Genzyme failed to act with due diligence, citing several delays and missteps throughout the regulatory review period.
- University of Michigan scientists and NIH funding were primarily responsible for the original invention and development of Cerdelga. Genzyme merely licensed and optimized the molecule, conducting limited clinical trials (with 186 total patients).
- Genzyme's incentives to delay development were financial—prolonging the regulatory review period increases the possible length of the patent extension.
- Cerdelga’s high cost ($300,000+/year) contributes to public burden and limits access to treatment.
- Generic entry would significantly reduce drug costs and increase public access.
- The petition includes substantial factual data, including FDA records, financial documents, media articles, and personal statements from the petitioner to support the claim of corporate overreach and lack of due diligence",,,2025-10-15,,,,,,no decision,2017,
fda-2017-p-3330,FDA-2017-P-3330-0001_Citizen_Petition_Regarding_PMA_K151763___REDACTED.pdf,,False,original petition,Anonymous (redacted),other,"- 21 U.S.C. §§ 321–397 (Food, Drug, and Cosmetic Act, general statutory authority)
- 21 C.F.R. § 10.30 (Citizen petition regulation)","The FDA’s clearance of 510(k) Premarket Notification K151763 for the PerioLase Nd:YAG Pulsed Dental Laser System, including acceptance of a new clinical outcome claim for “true periodontal regeneration” based on histologic data submitted by the manufacturer.","- The FDA is requested to reconsider, suspend, or revoke its clearance of 510(k) K151763.
- Specifically, the petitioner seeks a review of the clinical data accepted by FDA to support the indication for ""true regeneration""
","- The histologic data submitted was biased, lacked control groups, and included only studies funded by the manufacturer.
- No study demonstrated actual bone regeneration, and claims of superiority over conventional treatments (like Scaling and Root Planing) were unproven.
- The manufacturer’s marketing materials exaggerate FDA’s clearance, implying superiority rather than equivalency, which could mislead consumers and practitioners.
- The public may be misled to believe that this is the only device offering ""true regeneration"", despite lack of unbiased supporting evidence.
- The FDA is urged to protect public health by ensuring that all marketing claims are supported by rigorous, unbiased evidence and not simply by limited manufacturer-sponsored data",,,2025-10-15,,,,,,no decision,2017,
fda-2017-p-3352,FDA-2017-P-3352-0001_Citizen_Petition_from_Belcher_Pharmaceuticals__LLC.pdf,2017-05-25,False,original petition,"Belcher Pharmaceuticals, LLC",industry/corporation,"- 21 C.F.R. § 10.30 (Citizen petition procedure)
- 21 C.F.R. § 201.22(c) (Current sulfite warning regulation)
- 21 C.F.R. §§ 201.57, 201.100(d) (Labeling requirements)
- 21 C.F.R. § 25.31 (Environmental impact exclusion)
- Historical references: 50 Fed. Reg. 47,558 (1985); 51 Fed. Reg. 43,904 (1986)",FDA’s regulation in 21 C.F.R. § 201.22(c) that mandates the current sulfite warning labeling for epinephrine injection products used in emergency allergic situations.,"Amend 21 C.F.R. § 201.22(c) to update the sulfite warning language for epinephrine injections used in emergency situations. The updated warning should:
- Reflect the availability of sulfite-free epinephrine formulations.
- Avoid misleading implications that only sulfite-containing or non-epinephrine options exist.
- Emphasize that sulfite-free products should be used when available.","- The current regulation, written in 1986, is outdated and misleading; it implies no sulfite-free alternatives exist.
- Belcher's own sulfite-free epinephrine formulation (approved NDA 205029) has been FDA-approved and commercially available since 2014.
- Sulfite-sensitive patients are at risk from metabisulfite-containing formulations (e.g., Adrenalin®, EpiPen®), which can cause symptoms resembling or compounding anaphylaxis.
- Repeat dosing can exacerbate sulfite reactions and diminish drug efficacy.
- Sulfonate formation and metabolite persistence in the body can lead to delayed anaphylactic symptoms after treatment.
- Historical case studies show serious and prolonged adverse effects linked to sulfite-containing treatments.
- Physicians and patients need accurate labeling to make informed choices in emergencies, especially where safer alternatives are available",,,2025-10-15,0.0,,,,,no decision,2017,3065.0
fda-2017-p-3413,FDA-2017-P-3413-0001_Reclassification_Petition_from__Salter_Labs.pdf,2017-05-23,False,original petition,Salter Labs,advocacy/academic,"- 21 C.F.R. § 10.30 (Citizen petition procedure)
- 21 U.S.C. § 360c(e) (Section 513(e) of the FDCA – reclassification of devices)",FDA’s classification of oxygen conservers as Class II (special controls) medical devices.,The petitioner requests that the FDA reclassify oxygen conservers from Class II to Class I (general controls) devices .,"- Long-standing safety record of oxygen conservers over several decades.
- No documented safety or effectiveness concerns specific to the devices currently on the market.
- Current classification imposes unnecessary regulatory burdens that do not correspond to actual risk.
- Reclassification to Class I would align with the FDA’s goal of risk-based regulation and focus resources on higher-risk devices.
- Petition references 21 U.S.C. § 360c(e) as the legal basis for requesting reclassification when new information is available showing that special controls are unnecessary .",,,2025-10-15,0.0,,,,,no decision,2017,3067.0
fda-2017-p-3950,FDA-2017-P-3950-0001_Citizen_Petition_from__Amin_Talati_Upadhye_LLP__Fe.pdf,2017-06-21,True,original petition,Amin Talati Upadhye LLP,law/consulting,"- 21 C.F.R. § 10.30
- 21 U.S.C. § 355
- 21 C.F.R. §§ 25.30 and 25.31
- 21 CFR 314.94(a)(12)(viii)(C)(1)(ii)
- 21 CFR 314.95(b)(2)
- Section 505(j)(5)(B)(iv) of the FD&C Act",The potential approval of InnoPharma’s ANDA No. 207670 for levothyroxine injection before expiration of Fera’s 180-Day exclusivity,"The petitioner requests that the FDA not approve InnoPharma’s ANDA No. 207670 (and any other similar ANDAs) until Fera's 180-Day exclusivity has expired. They ask the FDA to confirm that InnoPharma is not entitled to ""first applicant"" status or shared exclusivity","- Fera submitted a timely ANDA with a Paragraph IV certification and sent the required notice letter.
- FDA recognized Fera as the first applicant in its 29 June 2016 approval letter.
- InnoPharma may have submitted its Paragraph IV certification and notice letter untimely or prematurely (before the patent was issued or listed in the Orange Book), thus invalidating its eligibility.
- Court records suggest InnoPharma’s Notice Letter was dated before the patent issued (09 April 2015 vs. 14 April 2015), which undermines its validity.
- Cited legal precedents and FDA guidance indicate that premature notice letters are invalid and can disqualify an applicant from exclusivity",12/18/2017,,2025-10-15,1.0,,,"- Pending Decision Due to Agency Priorities: FDA cites the need to address other agency priorities and resource constraints as the reason for not yet resolving the petition.
- Regulatory Compliance: Interim response issued pursuant to 21 CFR 10.30(e)(2)
",,no decision,2017,3038.0
fda-2017-p-4023,FDA-2017-P-4023-0001_Citizen_Petition_from_Sidley_Austin_LLP_Vifor_Fres.pdf,2017-06-30,True,original petition,Sidley Austin LLP,law/consulting,"- 21 C.F.R. § 10.30 (Citizen Petition regulation)
- Section 505 of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 U.S.C. § 352(a) (misbranding statute)
- 21 C.F.R. §§ 1.21, 202.1(e)(5)(iii) (promotion and labeling rules)
- 21 C.F.R. § 25.31 (Environmental impact exemption)
- 21 C.F.R. § 10.30(b) (Economic impact provision)","The pending supplemental New Drug Application (sNDA) filed by Keryx Biopharmaceuticals, Inc. in March 2017 seeking to expand Auryxia’s indication to include treatment of iron deficiency anemia (IDA) in non-dialysis dependent (NDD) chronic kidney disease (CKD) patients","The petitioner requests that the FDA refrain from approving the sNDA for Auryxia. Instead, the petitioner urges that Keryx be required to submit a separate NDA that includes adequate clinical and preclinical data to support the safety and appropriate labeling of Auryxia for IDA in NDD-CKD patients
","- Safety concerns: Use of Auryxia (a phosphate binder) in NDD-CKD patients with normal phosphorus levels is not recommended by guidelines and may pose risks such as iron overload and hypophosphatemia.
- Lack of long-term safety data: The clinical trial supporting the sNDA was only 16 weeks and did not address long-term risks of elevated iron stores (TSAT and ferritin).
- Labeling concerns: A dual-indication label (IDA and hyperphosphatemia) would be confusing and misleading, with each indication requiring monitoring for risks pertinent to the other.
- Regulatory precedent: It is unprecedented for one drug label to cover such distinct indications for different patient populations without misleading risk implications.
- Inconsistent mechanism of action: Ferric citrate’s behavior complicates safe dosing for multiple conditions simultaneously",,,2025-10-15,0.0,,,,,no decision,2017,3029.0
fda-2017-p-4027,FDA-2017-P-4027-0001_Citizen_Petition_from_Strides_Pharma_Inc.pdf,2017-07-01,False,original petition,Strides Pharma Inc.,industry/corporation,"- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31",Determination of whether METICORTEN (Prednisone) Tablets 1 mg and 5 mg (NDA N009766) were withdrawn from sale for reasons of safety or effectiveness,"- Determine whether METICORTEN (Prednisone) Tablets 1 mg was discontinued for safety or efficacy reasons
- If not, accept ANDA 210785 for Prednisone Tablets USP 1 mg for filing and approval using METICORTEN as the reference listed drug (RLD)","- METICORTEN Tablets are listed as ""Discontinued"" in the FDA's Orange Book without a stated reason
- The petitioner seeks clarity on whether the discontinuation was for safety or effectiveness reasons, as required for ANDA referencing
- Other generics for Prednisone 1 mg are already on the market, implying potential approval viability",,,2025-10-15,0.0,,,,,no decision,2017,3028.0
fda-2017-p-4039,FDA-2017-P-4039-0001_Citizen_Petition_from_Center_for_Lawful_Access_and.pdf,2017-07-03,False,original petition,Center for Lawful Access and Abuse Deterrence (CLAAD),law/consulting,"- 21 U.S.C. § 355(e) (FDCA section 505(e))
- 21 C.F.R. §§ 314.162, 5.10, 5.82
- 21 C.F.R. §§ 25.30(h), 25.31(h) (for environmental exclusion)","The petition comments on FDA’s current policy regarding the continued approval and marketing of non-abuse-deterrent opioid analgesics, and requests a change in enforcement to mandate conversion to abuse-deterrent formulations (ADOs).
","The petitioner asks the FDA to:
- Require manufacturers of certain non-abuse-deterrent oral opioid analgesics to convert to abuse-deterrent opioids (ADOs) within three years of the approval of a third ADO with the same active moiety.
- Remove products that are not converted within that time frame from the market.","- To mitigate the opioid overdose epidemic.
- To align with federal policy goals including those expressed by the Trump Administration and the FDA’s Opioids Action Plan.
- To address the public health and economic burden of opioid misuse and abuse.
- Because scientific advancements in ADOs and regulatory precedents (e.g., ER oxycodone case) support such a transition.",12/28/2017,,2025-10-15,1.0,,,"The FDA states that the petition raises “complex issues requiring extensive review and analysis by Agency officials.” Therefore, a decision has not yet been reached.

",,no decision,2017,3026.0
fda-2017-p-4145,FDA-2017-P-4145-0001_Citizen_Petition_from_Mylan_Pharmaceuticals__Inc.pdf,2017-07-07,False,original petition,Mylan Pharmaceuticals Inc.,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact categorical exclusion)","The petition comments on the FDA’s current classification of azacitidine injectable products, specifically the dosage strength of the Reference Listed Drug (RLD), Vidaza® (100 mg/vial), and seeks permission to submit a 50 mg/vial product under an ANDA (Abbreviated New Drug Application).
","To permit the submission of an ANDA for Azacitidine for Injection, 50 mg/vial, based on the approved RLD Vidaza® 100 mg/vial, reflecting a change in strength while maintaining the same proportion of active and inactive ingredients.
","- The change in strength (100 mg/vial to 50 mg/vial) is allowed under FDA regulations if it maintains proportionality with the RLD.
- The lower strength would provide greater dosing flexibility for physicians, based on hematological values.
- No concerns about safety or efficacy, as both products would be quantitatively and qualitatively equivalent.
- No change in route of administration or formulation—just a reduction in concentration and volume, with preserved proportions.",,,2025-10-15,0.0,,,,,no decision,2017,3022.0
fda-2017-p-4174,FDA-2017-P-4174-0001_Citizen_Petition_from_Mallinckrodt_Pharmaceuticals.pdf,2017-07-11,True,original petition,Mallinckrodt Pharmaceuticals,industry/corporation,"Federal Food, Drug, & Cosmetic Act (FDCA): Sections 210, 503, 505, 505(q), 510 (21 U.S.C. §§ 321, 353, 355, 360)  • ANDA provisions: 21 U.S.C. § 355(j)(2)(A)(v) and 21 C.F.R. § 314.94(a)(8)  • Citizen‑petition & guidance procedures: 21 C.F.R. Parts 3, 10 (incl. § 10.115(e), (f)(4), (g)(2))  • Combination‑product & device rules: 21 C.F.R. Parts 314, 800, 807  • Environmental & economic statements: 21 C.F.R. § 25.31  • APA notice‑and‑comment reference: 5 U.S.C. § 553 ","FDA’s acceptance for review and potential approval of follow‑on inhaled‑nitric‑oxide applications (e.g., ANDA 207141) that cite INOMAX as the reference listed drug, without first ensuring the associated delivery system meets critical safety features.	
","The petition asks FDA to: 1. Coordinate CDER + CDRH review of all future inhaled‑nitric‑oxide drug/device combination products; 2. Refuse to approve any NDA/ANDA citing INOMAX unless the drug‑device pair provides eleven specified safety features; 3. Assign a “BX” therapeutic‑equivalence rating to follow‑on nitric‑oxide products; and 4. Rescind receipt of Praxair’s ANDA 207141.	
","Mallinckrodt argues that inhaled nitric oxide is used in fragile neonates and that safety depends on integrated device features (dual‑channel monitoring, automated pre‑use checks, backup power, validated ventilator compatibility, 24/7 technical support, etc.). Approving a generic lacking those features would put patients at unnecessary risk and violate Hatch‑Waxman standards requiring generics to be as safe and effective as the RLD.	

",,,2025-10-15,0.0,,,,,no decision,2017,3018.0
fda-2017-p-4194,FDA-2017-P-4194-0001_Citizen_Petition_from_Lachman_Consultants_Services.pdf,2017-07-12,True,original petition,"Lachman Consultant Services, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. §§ 10.20, 10.30
- 21 C.F.R. § 25.31(a) (for environmental impact exclusion)","FDA's designation of reference listed drugs (RLDs) in the Orange Book and the absence of designation for a second RLD/RS for Halobetasol Propionate Ointment 0.05% when the existing RLD (Ultravate by Ranbaxy) is not available on the market.
","FDA should designate either of the following as a second reference listed drug/reference standard (RLD/RS) for Halobetasol Propionate Ointment 0.05%:
- ANDA A076872 held by Perrigo Israel Pharmaceuticals Ltd.
- ANDA A077721 held by G and W Laboratories Inc.","The currently designated RLD/RS, Ultravate (Halobetasol Propionate 0.05%) by Ranbaxy under NDA N019968, is not available on the market. This lack of availability prevents applicants from conducting required skin blanching studies, thus obstructing ANDA submissions. Since the Perrigo and G&W products are available, designating either as a second RLD/RS would allow for ANDA submissions and improve market access to generics.
",,,2025-10-15,0.0,,,,,no decision,2017,3017.0
fda-2017-p-4245,FDA-2017-P-4245-0001_Citizen_Petition_from_EAS_Consulting_Group__Jubila.pdf,2017-07-13,True,original petition,"EAS Consulting Group, LLC",industry/corporation,"- Federal Food, Drug, and Cosmetic Act (FDC Act) 505(j)
- 21 C.F.R. §§ 10.25(a), 10.30
- 21 C.F.R. § 25.31(a) (environmental impact)","Amendment of the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) to designate a new Reference Standard (RS) product
","FDA is requested to designate RS (Reference Standard) status to a currently available product for Fenofibrate Capsules 67 mg, 134 mg, and 200 mg in the market","The designated RS (Fenofibrate Capsules 200 mg by Rhodes Pharmaceuticals) is not available on the market. Petitioners intend to submit an ANDA and require a marketed RS product for in vivo bioequivalence studies. Thus, FDA should assign RS status to a therapeutically equivalent product currently on the market to enable generic development.

",1/12/2018,,2025-10-15,1.0,,,"The FDA stated that it was unable to reach a decision due to the need to address other agency priorities and resource demands
",,no decision,2017,3016.0
fda-2017-p-4249,FDA-2017-P-4249-0001_Suitability_Petition_from_GE_Healthcare_Inc.pdf,2017-07-07,True,original petition,GE Healthcare Inc.,industry/corporation,"- 21 U.S.C. § 355(j)(2)(c) (Section 505(j)(2)(c) of the FD&C Act)
- 21 CFR § 314.93
- 21 CFR §§ 10.20 and 10.30
- 21 CFR 25.31(a) (for environmental impact exclusion)","Evaluation of suitability for Abbreviated New Drug Application (ANDA) for Clariscan™ (gadoterate meglumine) 5mL vial size differing from the Reference Listed Drug (RLD) Dotarem® vial sizes (10, 15, 20 mL).
","The petitioner requests that FDA determine the proposed 5 mL vial size of Clariscan™ is suitable for submission in an ANDA
","- The 5 mL vial is needed for pediatric use (doses under 5 mL for children <25 kg).
- It reduces the risk of overdose and contamination from vial reuse.
- Aligns with body-weight-based dosing (0.2 mL/kg) of Dotarem®.
- No new safety or efficacy concerns are raised; only vial size differs.
- Potential to reduce environmental waste and healthcare costs
",,,2025-10-15,0.0,,,,,no decision,2017,3022.0
fda-2017-p-4351,FDA-2017-P-4351-0001_Citizen_Petition_from_Hogan_Lovells_US_LLP____Rely.pdf,2017-07-19,True,original petition,Hogan Lovells US LLP,law/consulting,"- 21 CFR Part 10.30
- Section 505(o), 505(o)(3), 505(o)(4), and 505(j)(2)(A)(v) of the FDCA (21 USC 355)
- 21 CFR 314.70(c)(6)(iii)(A)
- 21 CFR Part 201, including 21 CFR 201.100(d)(1), 201.57(c)(1), 201.57(c)(3)(i)(D)
- 21 USC 352(a), 352(f)(2)
- 5 USC 706(2)(A) (APA)","FDA’s failure to update the labeling of sodium polystyrene sulfonate (SPS) products like Kayexalate to include drug-drug interaction (DDI) warnings, despite previously issuing a safety alert in 2015 requiring DDI studies.
","The petitioner requests that the FDA:
- Require a boxed warning for SPS products, such as Kayexalate, disclosing the risk of binding with orally-administered medications.
- Include instructions that SPS should not be taken within six hours of other orally-administered drugs.
- Enforce labeling updates for SPS drugs under section 505(o)(4) and require drug-drug interaction studies under section 505(o)(3).","- FDA had already recognized DDI risks with SPS products in a 2015 safety communication.
- Relypsa’s own product, Veltassa, was required to carry a boxed warning and conduct DDI studies, but similar standards have not been applied to SPS drugs.
- The continued absence of boxed warnings and dosing window instructions on SPS products poses a public health risk.
- Unequal regulatory treatment between Veltassa and SPS products is arbitrary and capricious under the APA.
- Adequate warnings are necessary to inform prescribers and protect hyperkalemia patients from harmful drug interactions.",,,2025-10-15,0.0,,,,,no decision,2017,3010.0
fda-2017-p-4372,FDA-2017-P-4372-0002_Citizen_Petition_from_AEGIS_Regulatory__Inc_.pdf,,False,original petition,"AEGIS Regulatory, Inc.",industry/corporation,"- 21 C.F.R. § 10.30 (Citizen Petition)
- 21 C.F.R. § 70.3(s)
- 21 C.F.R. §§ 25.30–25.40","Enforcement and importation practices regarding cosmetic products, specifically the importation of adulterated foreign cosmetic products (notably ""Hair Pearl"" eyelash and eyebrow dye) containing coal tar dyes","- Prohibit the entry of adulterated cosmetic products (especially ""Hair Pearl"") into the U.S.
- Add the responsible companies in Germany to Import Alert 53-05.
- Instruct all FDA District Offices to refuse entry of such products","- Reports of adverse health effects including ocular erythema, chemically-induced conjunctivitis, and temporary blindness.
- Product illegally imported with falsified safety data sheets omitting known hazards.
- Violation of FDA regulations regarding color additives in products used around the eyes.
- Prior evasion of enforcement (e.g., Refectocil smuggled through US-Canadian border) cited as precedent for needed action",,,2025-10-15,,,,,,no decision,2017,
fda-2017-p-4389,FDA-2017-P-4389-0001_Citizen_Petition_from_Wildway_LLC.pdf,2017-07-21,False,original petition,"Wildway, LLC",industry/corporation,"- 21 C.F.R. § 101.60(c)(2)(v)
- Section 403(r)(4) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 101.60(b)
- 21 C.F.R. § 101.60(c)(2)(i–iv)
- 21 C.F.R. § 101.9(g)
- 21 C.F.R. § 25.32 (including § 25.32(p))",Regulation requiring products labeled with “No added sugar” to also include a statement that the product is not “low calorie” and to refer consumers to the nutrition panel,"To exempt certain Wildway food products from the requirement under 21 C.F.R. § 101.60(c)(2)(v) to declare:
> “The product bears a statement that the food is not ‘low calorie’ or ‘calorie reduced’ ... and that directs consumers' attention to the nutrition panel.”","- The new Nutrition Facts label (effective May 2016) already requires declaration of added sugars and their % Daily Value, rendering the additional statement redundant.
- The term “No added sugars” is consistent with the nutrition facts panel when it states “Includes 0g Added Sugars.”
- Requiring the extra disclaimer clutters the label and may mislead or confuse consumers.
- No products in the granola or cereal categories reasonably qualify as “low calorie” per 21 C.F.R. § 101.60(b); requiring a disclaimer for something that is clearly not expected misleads more than informs.
- FDA’s own statements support limiting excessive label information to avoid overwhelming consumers.
- Added sugars are a required declaration, not a claim, and should not require additional disclaimers.
- Wildway asserts this added disclaimer constitutes unnecessary regulatory burden with no public health benefit",,,2025-10-15,0.0,,,,,no decision,2017,3008.0
fda-2017-p-4575,FDA-2017-P-4575-0001_Vegetable_Oil_Health_Claim_petition_Nov_7_2016.pdf,2016-11-15,False,original petition,Unilever,industry/corporation,"- 21 C.F.R. § 101.70 (Health Claims; Petitions)
- Section 403(r)(3)(B)(i) of the Federal Food, Drug, and Cosmetic Act (FFDCA)","FDA's regulatory framework for approving health claims related to dietary fats and oils, particularly concerning the relationship between unsaturated fatty acids and coronary heart disease risk","Approve a new health claim stating that oils high in unsaturated fats may reduce the risk of coronary heart disease when replacing saturated fat, as part of a healthy diet
","- Scientific evidence supports a favorable association between dietary intake of unsaturated fatty acids and reduced risk of coronary heart disease (CHD).
- The petition includes over 80 peer-reviewed human intervention and observational studies.
- FDA had previously approved a similar claim for canola oil, and this request seeks to broaden it to include soybean, sunflower, corn, and other vegetable oils.
- Approval would improve public health messaging by aligning dietary guidance with regulatory standards",8/4/2017,,2025-10-15,1.0,,,"Not Provided – This is an interim response only confirming the petition was filed. No substantive justification or evaluation is included.
",,no decision,2017,3256.0
fda-2017-p-4791,FDA-2017-P-4791-0001_Citizen_Petition_from_Hyman__Phelps____McNamara__P.pdf,2017-08-08,True,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.3(b)
- 21 C.F.R. § 314.94(a)(9)(iii)
- Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- FDCA § 736(a)(2)(A)
- FDCA § 736(a)(3)(A)
- FDCA § 736(a)(3)(B)
- FDCA § 736(i)
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)","Assignment of a Therapeutic Equivalence (TE) Code in the FDA’s Orange Book for Exela’s NDA 209463 (Pantoprazole Sodium for Injection, 40 mg/vial)
","FDA should assign a TE Code of “AP” to Exela’s Pantoprazole Sodium for Injection (NDA 209463) in the Orange Book
","- Exela’s product is pharmaceutically equivalent and bioequivalent to Wyeth’s PROTONIX I.V. (NDA 020988).
- Exela’s NDA 209463 was approved under FDCA § 505(b)(2) due to a formulation difference (absence of edetate disodium).
- FDA waived the requirement for in vivo bioequivalence studies.
- Assignment of the TE Code would exempt Exela from certain user fees.",2/1/2018,,2025-10-15,1.0,,,"- FDA cited the need to address other Agency priorities as the reason for not yet resolving the petition.
- FDA affirmed it would respond as soon as possible.",,no decision,2017,2990.0
fda-2017-p-5080,FDA-2017-P-5080-0001_Citizen_Petition_from_Quagen_Pharmaceuticals_LLC.pdf,2017-08-17,True,original petition,Quagen Pharmaceuticals LLC,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. §§ 10.20, 10.30 (Citizen petition process)
- 21 C.F.R. § 25.31(a) (Environmental assessment exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact disclosure)","The designation in the Orange Book of Xylocaine® (Lidocaine) Ointment, 5% by AstraZeneca as the Reference Listed Drug (RLD) — despite its market unavailability — and Fougera Pharmaceuticals’ product (ANDA 080198) being designated only as a Reference Standard (RS)","FDA should designate Lidocaine Ointment, 5% of Fougera Pharmaceuticals Inc. (ANDA 080198) as a Reference Listed Drug (RLD) instead of merely a Reference Standard
","- Xylocaine® Ointment, the current RLD, is no longer available in the market, making it impossible for ANDA applicants to conduct product development studies.
- The Orange Book Preface allows for designation of a second RLD if the original is unavailable for bioequivalence testing.
- Fougera’s product is already designated as RS, and designating it as RLD would facilitate ANDA submissions.
- This designation supports regulatory clarity and generic competition",2/12/2018,,2025-10-15,1.0,,,"The FDA stated it has been unable to reach a decision on the petition due to the need to address other agency priorities. The interim response was issued in accordance with 21 CFR 10.30(e)(2), and the agency committed to responding as soon as possible given resource constraints. The petition requested that lidocaine ointment, 5% (ANDA 080198), be designated as a Reference Listed Drug in the Orange Book.

",,no decision,2017,2981.0
fda-2017-p-5082,FDA-2017-P-5082-0001_Citizen_Petition_from__ChromaDex__Inc_.pdf,2017-08-18,False,original petition,"ChromaDex, Inc.",industry/corporation,"- 21 C.F.R. §§ 10.25, 10.30 (Citizen petition procedure)
- 21 U.S.C. § 342(a)(1), 342(f), 342(f)(1)(B), 350b (Adulterated foods & new dietary ingredients)
- 21 U.S.C. §§ 332, 334 (Enforcement mechanisms: injunction & seizure)
- 21 C.F.R. § 190.6 (New Dietary Ingredient Notification)
- 21 C.F.R. § 173 Subpart C (Food additives: solvents)
- 21 C.F.R. § 25.32 (Environmental impact exclusion)","Continued marketing and distribution of Elysium Health’s Basis product, alleged to contain undeclared toluene and an unapproved new dietary ingredient","- Declare Basis adulterated under 21 U.S.C. § 342
- Halt distribution and seize product
- Enjoin manufacturers/distributors under 21 U.S.C. §§ 332, 334
- Determine the unapproved ingredient (nicotinamide riboside) violates 21 U.S.C. § 350b, due to lack of NDI filing","- Laboratory analysis revealed Basis contains 96–144 mg/kg of toluene, a toxic industrial solvent not approved for ingestion
- Elysium switched to a non-NIAGEN® nicotinamide riboside supplier with no FDA-recognized GRAS or NDIN
- Chemical, packaging, and compositional discrepancies were confirmed through testing (e.g., solvents, impurities, metals, label differences)
- Petition argues Elysium has not met FDA’s safety requirements for new dietary ingredients and is selling a product potentially injurious to health",2/15/2018,,2025-10-15,1.0,,,"The FDA has not made a decision on the petition within the first 180 days due to competing agency priorities. However, the petition is currently under active evaluation
",,no decision,2017,2980.0
fda-2017-p-5118,FDA-2017-P-5118-0001_Citizen_Petition_from_Tricia_Thompson_Redacted.pdf,2017-08-18,False,original petition,"Gluten Free Watchdog, LLC",industry/corporation,"- Section 201(n), 301–303, and 403(a)(1) of the Federal Food, Drug, and Cosmetic Act (FFDCA); 21 U.S.C. §§ 321(n), 331–333, and 343(a)(1)
- 21 C.F.R. Part 101.91 (Gluten-Free Labeling Rule)","Enforcement and compliance efforts under the Gluten-Free Labeling Rule, particularly relating to the labeling of products that are “gluten-free” despite containing prohibited ingredients such as barley malt, malt extract, and wheat
","- Establish a specific protocol for increased surveillance, investigation, and enforcement of “Facial Misbranding” violations under the Gluten-Free Labeling Rule
- Implement an online reporting system for consumers to submit label violations
- Issue FDA Warning Letters within 30 days of receiving reports
- Alternatively, initiate a “Facial Misbranding Initiative” akin to the Front of Package Labeling Initiative","- Persistent misbranding issues with gluten-free labeled products that actually contain gluten ingredients
- Current consumer reporting mechanisms are inadequate and not prioritized
- Misbranded products remain on shelves despite FDA awareness
- Enhanced enforcement is essential for protecting individuals with celiac disease
- A structured and visible FDA protocol will deter violations and ensure labeling compliance",2/13/2018,,2025-10-15,1.0,,,"The FDA has not reached a decision on the petition due to competing agency priorities. The agency states the petition is currently under active evaluation by its staff
",,no decision,2017,2980.0
fda-2017-p-5335,FDA-2017-P-5335-0001_Citizen_Petition_from_ANDA_Consultants.pdf,2017-08-29,False,original petition,ANDA Consultants,law/consulting,"- 21 C.F.R. § 10.25(a)(2)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.122
- 21 C.F.R. § 314.161
- 21 C.F.R. § 25.31 (categorical exclusion – environmental impact)
- 21 C.F.R. § 10.30(b) (economic impact disclosure)","The status in the Orange Book of Nexiclon™ XR (clonidine) Extended Release Tablets, NDA 22-500, which is listed as discontinued. The petitioner questions whether this discontinuation was due to safety or effectiveness reasons","The petitioner asks the FDA to determine that NDA 22-500 was not withdrawn for reasons of safety or effectiveness, so that it can be used as a reference listed drug (RLD) in ANDA submissions","- NDA 22-500 (Nexiclon™ XR) is currently in the Discontinued section of the Orange Book.
- The petitioner asserts there is no indication that the discontinuation was due to safety or efficacy concerns.
- A formal FDA determination is needed so that generic applicants can reference this NDA in their ANDAs",,,2025-10-15,0.0,,,,,no decision,2017,2969.0
fda-2017-p-5370,FDA-2017-P-5370-0001_Citizen_Petition_from_Dennis_Ryll_Redacted.pdf,2017-08-01,True,original petition,"Dennis L. Ryll, MD",individual,"- 21 C.F.R. § 10.30 (Citizen Petition regulation)
- 21 U.S.C. § 355(e) (Drug withdrawal and labeling changes)
- FDAAA § 505(o)(4) (Authority to mandate labeling changes)
- 21 C.F.R. § 25.31(a) (Environmental impact categorical exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact submission)","FDA’s existing labeling and risk communication practices for Schedule II (CII) opioid analgesics. Specifically, the lack of a warning comparing risk between CII and CIII opioids
","The petitioner requests FDA to:
- Add a black box warning to all CII opioid analgesics stating that a CIII opioid should be tried first to reduce the risk of addiction and overdose.
- Require medication guides for CII opioids that explain their higher risk relative to CIII opioids, and emphasize usage limits","- CII opioids are “pure agonists” that strongly bind to Mu receptors, leading to high euphoria, addiction, and respiratory depression.
- CIII opioids like buprenorphine are “partial agonists” with a ceiling effect on respiratory depression and are less likely to cause overdose or addiction.
- Scientific studies cited show lower abuse potential, lower overdose rates, and lower physical dependence with buprenorphine.
- Despite buprenorphine’s safety and effectiveness, it remains underprescribed (under 1% of opioid prescriptions).
- A black box warning and revised guidance would promote safer prescribing and align with FDA’s public health mission amid the opioid crisis",2/26/2018,,2025-10-15,1.0,,,"The petition raises complex issues that require extensive review and analysis by FDA officials. As such, a decision has not yet been made, but the petition remains under consideration
",,no decision,2017,2997.0
fda-2017-p-5396,FDA-2017-P-5396-0001_Citizen_Petition_from_Physicians_for_Responsible_O.pdf,,False,original petition,"Multiple co-signatories:  Andrew Kolodny, M.D., Executive Director, Physicians for Responsible Opioid Prescribing (PROP)  Jay Butler, M.D., President, Association of State and Territorial Health Officials  Deborah A.P. Hersman, President & CEO, National Safety Council  Charles McKay, M.D., FACMT, President, American College of Medical Toxicology  Judy Rummler, Chair, FED UP! Coalition  Gary Mendell, Founder and CEO, Shatterproof",advocacy/academic,"- 21 C.F.R. § 10.30 (citizen petition regulation)
- 21 U.S.C. § 355(e) (section of the FD&C Act governing drug withdrawal)
- 21 C.F.R. § 25.31(a) (environmental impact categorical exclusion)
- Executive documents and public health reports also cited for context (e.g., CDC guidelines, National Academies recommendations)","The continued market availability of ultra-high dosage unit (UHDU) orally and transmucosally administered opioid analgesics, such as OxyContin 80 mg, IR oxycodone 30 mg, and others with daily doses exceeding 90 MME/day","The petitioners request that the FDA:
- Immediately seek removal of UHDU oral and transmucosal opioid analgesics from the U.S. market
","- UHDU opioids exceed safe dosing levels (CDC: >90 MME/day).
- They pose high risks for misuse, accidental overdose, and death, especially among opioid-naïve users, children, and adolescents.
- Studies show increased risk of overdose, addiction, and other adverse events at high dosages without proportional benefits in pain control.
- Removing UHDUs could reduce morbidity and mortality, reverse risky prescribing norms, and have minimal burden on legitimate patients, who can use smaller doses or alternative formulations (e.g., liquids, patches).
- Aligns with FDA’s new benefit-risk framework that weighs public health impact of misuse",,,2025-10-15,,,,,,no decision,2017,
fda-2017-p-5435,FDA-2017-P-5435-0001_Citizen_Petition_from_Hyman__Phelps___McNamara_PC.pdf,2017-09-01,True,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.3
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)
- FD&C Act § 505(j)
- Referenced: FDA Draft Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions (Jan. 2017)","The designation of Reference Standards (RS) in the Orange Book—specifically, whether the 500 mg strength of Amicar (NDA 015197) should be designated as a new RS","FDA should designate Amicar (aminocaproic acid) Tablets, 500 mg, NDA 015197, as a Reference Standard (RS) in the Orange Book to support ANDA submissions
","- The current RS (aminocaproic acid 1g tablets under NDA 015197) is difficult to obtain in the U.S.
- The 500 mg strength is already listed as an RLD but not as an RS.
- This limits generic competition.
- FDA guidance allows RS changes to facilitate ANDA development.
- Designating the 500 mg strength as an RS would help promote market competition and ensure availability for in vivo testing",,,2025-10-15,0.0,,,,,no decision,2017,2966.0
fda-2017-p-5592,FDA-2017-P-5592-0001_Citizens_Petition_from_International_Isotopes_Inc.pdf,2017-09-06,False,original petition,International Isotopes Inc.,industry/corporation,"- Section 505(j) of the FD&C Act
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.93
- 21 C.F.R. § 25.31 (environmental exclusion)
- 21 C.F.R. § 10.30(b) (economic impact disclosure)","The listing status of Sodium Iodide I-123 Solution, 2 mCi/ml, NDA 017630 in the Orange Book, specifically whether its discontinuation was due to safety or efficacy concerns","Request for FDA to:
- Determine that Sodium Iodide I-123 Solution (2 mCi/ml, NDA 017630) was not discontinued for safety or efficacy reasons
- Publish this determination in the Federal Register
- Amend the Orange Book to list the product as a Reference Listed Drug (RLD)","- Product is listed as discontinued but no evidence indicates GE Healthcare discontinued it for safety or efficacy reasons.
- Petitioner cites FDA’s policy of designating market leaders as RLDs.
- The solution form offers more flexible dosing than fixed-dose capsules (100/200 µCi).
- The proposed manufacturing method would improve the purity of the radioactive product.
- There is currently no RLD available for ANDA applicants for this solution strength, hindering generic development
",3/8/2018,,2025-10-15,1.0,,,"The FDA has not reached a decision due to the need to address other agency priorities. The petition, which requested a determination that Sodium Iodide I-123 oral solution was not discontinued for safety or effectiveness reasons, is still under review
",,no decision,2017,2961.0
fda-2017-p-5921,FDA-2017-P-5921-0001_Citizen_Petition_from_Arent_Fox.pdf,2017-09-20,True,original petition,Arent Fox LLP,law/consulting,"- 21 C.F.R. § 10.25
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.161
- 21 C.F.R. § 314.162
- 21 C.F.R. § 25.31","The FDA’s Reference Listed Drug (RLD) designation for Midodrine Tablets in the Orange Book. Specifically, the petition challenges the continued designation of Shire's ProAmatine® as the sole RLD, and requests recognition of Sandoz’s ANDA product as a new or additional Reference Standard (RS)
","- That FDA designate Sandoz’s Midodrine Tablets (ANDA 090832) as a new or additional Reference Standard (RS) for Midodrine in the Orange Book.
- That FDA determine Mylan’s Midodrine Tablets (ANDA 090854) were not withdrawn for safety or effectiveness reasons","- Shire's NDA product (ProAmatine) is no longer marketed and was withdrawn from sale since at least 2011, per the Orange Book listing.
- FDA's guidance permits an ANDA product to serve as an RS if the RLD is unavailable.
- Sandoz’s product and Mylan’s product were both approved and marketed, meet bioequivalence standards, and have consistent safety/effectiveness profiles.
- Ensuring continuity in generic competition and public access is important, and FDA has recognized similar designations in past cases",,,2025-10-15,0.0,,,,,no decision,2017,2947.0
fda-2017-p-5947,FDA-2017-P-5947-0001_Citizen_Petition_from_Teligent_Pharma_Inc_2.pdf,2017-09-25,True,original petition,"Teligent Pharma, Inc.",industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
- 21 C.F.R. §§ 10.20 and 10.30
- 21 C.F.R. § 25.31(a) (for environmental impact exclusion)","The FDA's designation of a single Reference Listed Drug/Reference Standard (RLD/RS) in the Orange Book—specifically NDA 019716 (Diprolene® Lotion 0.05%) by Merck Sharp Dohme—as the only RLD/RS for generic applications.
","The petitioner requests FDA to designate either ANDA 077111 (held by Fougera Pharmaceuticals, Inc.) or ANDA 077477 (held by Taro Pharmaceuticals USA, Inc.) as a second RLD/RS for Betamethasone Dipropionate Lotion USP 0.05% (Augmented).","- The currently designated RLD/RS (Diprolene®, NDA 019716) is not marketed and therefore unavailable for bioequivalence studies.
- This prevents ANDA submissions based on the RLD/RS.
- Both proposed alternatives are marketed and accessible, thus facilitating generic development.",3/22/2018,,2025-10-15,1.0,,,"- The petition requests that the FDA designate either ANDA 077111 or ANDA 077477 for Betamethasone Dipropionate Lotion USP 0.05% (Augmented) as a second RLD/RS product for ANDA submissions.
- FDA indicates that this issue involves complex scientific and regulatory considerations requiring detailed review before a final decision can be made",,no decision,2017,2942.0
fda-2017-p-5978,FDA-2017-P-5978-0001_Citizen_Petition_from_JR_Rapoza_Associates__Inc_.pdf,2017-09-24,True,original petition,"JR Rapoza Associates, Inc.",industry/corporation,"- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.161
- 21 C.F.R. § 25.31 (for environmental impact)","Establishment of a new Reference Standard Drug in the Orange Book for Cardene® (nicardipine hydrochloride) Injection 25 mg/10 mL vial, NDA 019734
","That the FDA make a determination for listing a Generic Drug Product as the Reference Standard Drug for Cardene® Injection 25mg/10mL in the Orange Book, to support filing of a bioequivalent ANDA
","- The original NDA product was discontinued for reasons other than safety or efficacy when Chiesi USA, Inc. moved to premixed solutions.
- The discontinued product is not currently listed in the Orange Book as discontinued.
- Other bioequivalent products are available and could serve as Reference Standard.
- The petitioner believes that approval of the larger vial size would bring economic and dosing convenience benefits",3/26/2018,,2025-10-15,1.0,,,"- The petitioner requested that the FDA designate a new reference standard for nicardipine hydrochloride injection 25 mg/10 mL USP in the Orange Book.
- FDA stated it had been unable to reach a decision due to the need to address other Agency priorities",,no decision,2017,2943.0
fda-2017-p-6208,FDA-2017-P-6208-0001_Citizen_Petition_from_INC_Research_inVentiv_Health.pdf,2017-10-18,True,original petition,INC Research/inVentiv Health,industry/corporation,"- 21 C.F.R. §§ 10.25, 10.30, 314.122, 314.161
- 21 C.F.R. § 25.31(a) (environmental impact)
- Section 505(j)(7) and 505(j)(2) of the FD&C Act","Determination of whether the reference listed drug (RLD) Theophylline Extended Release Tablets (100 mg and 200 mg) has been discontinued for safety or effectiveness reasons, and recommending a reference standard for bioequivalence studies due to current RS shortage.
","- A determination that the shortage/unavailability of Theophylline ER Tablets (ANDA# A89807 and A89808) is due to cGMP issues
- FDA should recommend a suitable reference standard to be relied upon for an ANDA submission and fasting bioequivalence study for these products","- Pliva, the RS holder, is not manufacturing the drug due to cGMP issues.
- Another approved ANDA holder, Nostrum, lacks NDC numbers in the FDA’s data directory.
- An RS is needed for bioequivalence studies required for ANDA submission.
- This situation meets the criteria for regulatory consideration under 21 CFR 314.122 & 314.161",4/12/2018,,2025-10-15,1.0,,,"The petition raises complex issues that require extensive review and analysis by Agency officials, preventing the FDA from issuing a final decision at this time.

",,no decision,2017,2919.0
fda-2017-p-6211,FDA-2017-P-6211-0001_Citizen_Petition_from_DSM_Nutritional_Products_LLC.pdf,,False,original petition,DSM Nutritional Products LLC,industry/corporation,"- 5 U.S.C. § 553(e) (Administrative Procedure Act)
- 21 C.F.R. §§ 10.25 and 10.30
- Sections 201(n), 403A, and 701(a) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 101.9(c)(8)(v) (subject of amendment request)
- Also referenced within text: 21 C.F.R. §§ 104.20, 101.36, 172, 182, 184, 107.10, 130–169","Existing FDA regulations that require complex chemical nomenclature on Nutrition and Supplement Facts labels and Ingredient Declarations.
","DSM requests that the FDA amend 21 C.F.R. 101.9(c)(8)(v) to allow for the use of simple vitamin letter names (e.g., Vitamin C, B1, B2) on Nutrition/Supplement Facts labels and Ingredient Declaration lines
","- Consumers are confused by chemical names (e.g., “ascorbic acid” vs. “Vitamin C”)
- Surveys show consumers rate chemical names as less healthy or are unaware of their meaning
- Simple names improve clarity and recognition of nutrient-fortified products
- Simplified labels reduce space and increase appeal and trust in products
- Harmonizes label language between Nutrition Facts and Ingredient Declaration
- Promotes consumption of nutrient-dense foods and public health",,,2025-10-15,,,,,,no decision,2017,
fda-2017-p-6219,FDA-2017-P-6219-0001_Citizen_Petition_from_Axinn__Veltrop___Harkrider_L.pdf,2017-10-19,True,original petition,"Axinn, Veltrop & Harkrider LLP",law/consulting,"- Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act
- 21 C.F.R. § 314.93 – Suitability petitions
- 21 C.F.R. §§ 10.20 and 10.30 – Citizen petition procedures
- 21 C.F.R. § 25.31 – Categorical exclusion for environmental impact
- 21 C.F.R. § 10.30(b) – Economic impact requirements","FDA’s current stance requiring an approved suitability petition before allowing submission of an ANDA for a drug product that differs from the RLD in strength; specifically, requesting approval for Hydromorphone HCl ER tablets in 24 mg strength, based on the RLD Exalgo® 32 mg
","FDA should approve a suitability petition to allow submission of an ANDA for Hydromorphone HCl extended-release tablets, 24 mg, which differs only in strength from the RLD (Exalgo® 32 mg, NDA 21217)
","- The proposed 24 mg strength differs only in strength and inert excipients, with similar in vitro dissolution and pharmacokinetics.
- An intermediate dose fills the gap between 16 mg and 32 mg RLD strengths, improving dosing flexibility.
- Reduces need for patients to combine multiple strengths, minimizing risk of misuse, overdose, or sub-therapeutic dosing.
- No changes in labeling other than strength and manufacturer-specific information",,,2025-10-15,0.0,,,,,no decision,2017,2918.0
fda-2017-p-6245,FDA-2017-P-6245-0001_Citizen_Petition_from_ViGuard_Health_Inc_.pdf,2017-10-23,True,original petition,ViGuard Health Inc.,industry/corporation,"- 21 C.F.R. § 10.30
- 21 U.S.C. § 321(ff)(1)(A)
- 21 U.S.C. § 321(ff)(3)(B)(ii)
- 21 C.F.R. § 25.22
- 21 C.F.R. § 25.24(a)(11)
- Dietary Supplement Health and Education Act of 1994 (DSHEA)","FDA's prior stance that pyridoxamine is not a dietary supplement due to its prior investigation as a drug under an IND, specifically the application by BioStratum Inc. and the resulting exclusion under the ""prior market clause"" in 21 U.S.C. § 321(ff)(3)(B)
","1. Declare that pyridoxamine is no longer an article authorized for investigation as a new drug and is thus not excluded from the definition of a dietary supplement under 21 U.S.C. § 321(ff)(3)(B)(ii).
2. If not, exercise discretion to create an exception allowing pyridoxamine to be marketed as a dietary supplement.
3. Affirm pyridoxamine is a vitamin under 21 U.S.C. § 321(ff)(1)(A).","- Pyridoxamine is a naturally occurring vitamer of vitamin B6, now free from any active INDs.
- Previous drug development efforts (by BioStratum and NephroGenex) were abandoned due to lack of funding and efficacy.
- ViGuard aims to market pyridoxamine as a dietary supplement, aligning with the intent of DSHEA.
- The FDA has discretionary authority to make exceptions.
- Continued exclusion under the ""prior market clause"" would be unfair, unnecessary, and contrary to public health interests and Congressional intent to promote dietary supplement innovation
",4/25/2018,,2025-10-15,1.0,,,"The FDA cites ""competing agency priorities"" as the reason for not reaching a decision within 180 days. The petition remains under active evaluation.

",,no decision,2017,2914.0
fda-2017-p-6357,FDA-2017-P-6357-0001_Citizen_Petition_from_Diana_Wierzchos_Redacted.pdf,2016-09-15,False,original petition,Diana Wierzchos,individual,"- The petition is submitted under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act (no specific sections cited)
","The petitioner calls for the FDA to reform the U.S. food supply system, specifically regarding factory farming practices. The action is not in response to a specific FDA policy but a general petition to influence national food regulation standards, animal treatment policies, and public health considerations
","- Replace or drastically reduce the use of concentrated animal feeding operations (CAFOs)
- Promote alternative, humane food production methods that are more sustainable and health-conscious
- Encourage legal reform to improve environmental, human, and animal health outcomes
- Address problems associated with subsidized factory farming","- Health risks: Links between red meat consumption and chronic diseases (e.g., cancer, diabetes, cardiovascular conditions)

- Food safety: Issues with contamination and poor hygiene in meat processing (e.g., fecal bacteria, TMAO production, drug-resistant infections)
- Environmental impact: CAFOs generate significant greenhouse gas emissions, deforestation, and water/soil pollution

- Animal welfare: Inhumane treatment, high animal mortality, and lack of rights protections
- Economic & social concerns: Industrial farming undermines small farms and consumer rights; supports unsustainable systems with public subsidies
- The petitioner urges the FDA to address these interconnected issues systemically.",,,2025-10-15,0.0,,,,,no decision,2017,3317.0
fda-2017-p-6631,FDA-2017-P-6631-0001_Citizen_Petition_from_Amin_Talati_Upadhye_LLP__Nat.pdf,2017-11-27,False,original petition,Amin Talati Upadhye LLP,law/consulting,"- 21 C.F.R. §§ 10.25 and 10.30 (Citizen petition authority)
- 21 U.S.C. § 321(ff)(1) (definition of dietary supplement)
- 21 U.S.C. §§ 343, 301(a), 332, 334 (misbranding, adulteration, injunctions, seizure)
- 21 U.S.C. § 350b (new dietary ingredient - NDI)
- 21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 355(b), 352(f)(1), 352(o), 360, 351(a)(2)(B) (drug definition, unapproved drugs, misbranding, GMPs)
- 21 C.F.R. § 25.32 (environmental exemption)","FDA’s lack of regulatory enforcement against Cardax Inc. regarding its sale of ZanthoSyn, a product alleged to be misbranded, adulterated, and an unapproved new drug containing synthetic astaxanthin. The petitioner argues FDA should not allow the product to be marketed as a dietary supplement or drug without proper approval or safety evaluation","- Determine ZanthoSyn is misbranded under 21 U.S.C. § 343 (not a dietary supplement)
- If considered a supplement, declare it adulterated due to unnotified new dietary ingredient (NDI)
- Declare ZanthoSyn is an unapproved new drug under 21 U.S.C. §§ 321(g), 355(b), 331(d)
- Take enforcement actions under 21 U.S.C. §§ 332, 334 (injunction, seizure)
- Require Cardax to cease distribution of ZanthoSyn","- Synthetic astaxanthin is not a lawful “dietary ingredient” under the FD&C Act; it is neither derived from natural botanical sources nor part of the conventional food supply.
- Even if considered a dietary ingredient, it is an NDI without notification, and no sufficient safety evidence exists.
- ZanthoSyn bears drug-like disease claims (e.g., anti-inflammatory, cholesterol lowering), making it an unapproved new drug.
- The safety and efficacy of synthetic astaxanthin is unproven, with claims based on unrelated studies.
- Consumers are misled by “physician endorsed” and “safe” claims, increasing public health risk
",,,2025-10-15,0.0,,,,,no decision,2017,2879.0
fda-2017-p-6649,FDA-2017-P-6649-0001_Citizen_Petition_from_Greenberg_Traurig_LLP___on_b.pdf,2017-11-28,True,original petition,Greenberg Traurig LLP,law/consulting,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. § 10.30 (Citizen Petition regulation)
- 21 C.F.R. § 314.3(b) (definition of listed drugs)
- 21 C.F.R. § 314.127(a)(6)(i) (ANDA requirements)
- 21 C.F.R. § 314.161(a)(1) (withdrawal for safety or efficacy reasons)
- 21 C.F.R. §§ 25.30 and 25.31 (environmental exemption)","Approval of Abbreviated New Drug Applications (ANDAs) that refer to the discontinued two-ingredient formulation of KINEVAC for injection. The petitioner requests the FDA to recognize that the formulation was withdrawn for safety and efficacy reasons, thereby disqualifying it as a Reference Listed Drug (RLD)
","- FDA should determine that the two-ingredient KINEVAC formulation was discontinued for safety and efficacy reasons
- FDA should declare that any generic referencing this formulation would be less safe and effective
- FDA should determine that the formulation is not a suitable RLD
- FDA should not accept or approve any ANDA referencing the discontinued formulation","- The discontinued formulation was unstable, degrading significantly before its labeled shelf life, leading to variable potency
- Impaired diagnostic reliability in gallbladder imaging tests (e.g., CCK-CS) could result in false-positive diagnoses and unnecessary surgeries
- The new formulation is more chemically stable, has a better impurity profile, and supports an established Practice Guideline
- Using the discontinued version would undermine clinical standards and patient safety",,,2025-10-15,0.0,,,,,no decision,2017,2878.0
fda-2017-p-6663,FDA-2017-P-6663-0001_Citizen_Petition_from_Dr__Edwards_Redacted.pdf,,False,original petition,"Dr. S. Albert Edwards, PharmD, RAC, FRAPS",individual,"- 21 CFR 5.10 – Delegation of authority to request FDA action
- Medical Device Amendments to the FD&C Act
- 21 CFR 30.10(b)(D) – Certification section
- 21 CFR 25.34 – Environmental categorical exclusion","- Marketing of unapproved annuloplasty rings (Myxo ET Logix 5100 / dETLogix 5110) without 510(k) or PMA approval (2007–2009)
- FDA's approval in April 2009 with no retroactive sanctions","- Investigate Edwards Lifesciences’ marketing of unapproved medical devices
- Compare regulatory vs. patent application histories
- Require FDA review staff to track patent data vs. 510(k)/PMA statements
- Review the JTF File for inconsistencies","- Implanted device was investigational at time of surgery
- No response to inquiries from Edwards or FDA
- FOIA request confirmed lack of 510(k)
- History of regulatory noncompliance
- Claimed “same technology” contradicted by 40 differences in patent filings
- Public health risk due to lack of transparency and enforcement",,,2025-10-15,,,,,,no decision,2017,
fda-2017-p-6751,FDA-2017-P-6751-0001_Citizen_Petition_from_Capstone_Law_APC_on_behalf_o.pdf,2017-12-05,False,original petition,Capstone Law APC,law/consulting,"- 21 U.S.C. § 343 (FDCA § 403)
- 21 C.F.R. § 10.60
- 21 C.F.R. § 101.3(e)
- 21 C.F.R. § 101.3(e)(4)
- 21 C.F.R. § 130.10
- 21 C.F.R. §§ 25.30–25.34 (environmental exclusions)
- 21 C.F.R. § 101.9
- Section 401 of the FDCA","FDA’s regulatory approach and lack of enforcement concerning the labeling of non-dairy milk alternatives (specifically Silk Almondmilk) as “imitation milk”, and whether FDA will accept or reject a court referral for guidance in the matter
","FDA is requested to:
1. Determine or issue guidance on whether Silk Almondmilk ""substitutes for, resembles, and is nutritionally inferior to"" milk.
2. Require it to be labeled as “imitation milk” under 21 C.F.R. § 101.3(e).
3. Promptly respond to the court referral under 21 C.F.R. § 10.60 from a related class action lawsuit","- Silk Almondmilk resembles and substitutes for milk in packaging, placement, advertising, and usage.
- It is nutritionally inferior to dairy milk across essential nutrients including protein, magnesium, potassium, phosphorus, zinc, and several vitamins (as shown in a detailed nutritional comparison table on page 6).
- Consumers are misled by use of the term “milk” in the product’s identity despite its inferiority.
- FDA precedent and prior guidance support labeling such products as “imitation” when they fail to meet nutritional equivalency.
- Regulatory clarity is needed as courts have deferred to FDA on these labeling issues",6/7/2018,,2025-10-15,1.0,,,The FDA stated it could not reach a decision within 180 days of the petition’s receipt or by the date of the letter due to other competing agency priorities. The agency will continue reviewing the petition and consider issuing guidance as warranted within the context of other program priorities,,no decision,2017,2871.0
fda-2017-p-6777,FDA-2017-P-6777-0001_Citizen_Petition_from_Hyman__Phelps___McNamara__P_.pdf,2017-12-06,True,original petition,"Hyman, Phelps & McNamara, P.C.",law/consulting,"- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- Section 505(b)(2) of the FDCA
- 21 C.F.R. § 314.3(b)
- 21 C.F.R. § 25.31
- 21 C.F.R. § 10.30(b)","FDA’s assignment (or lack thereof) of a Therapeutic Equivalence (TE) Code in the Orange Book for Xellia's Daptomycin for Injection, 350 mg/vial, NDA 209949
","- Assign a TE Code ""BX"" to Xellia’s Daptomycin for Injection, 350 mg/vial, in the Orange Book.
- If adequate evidence becomes available, consider TE Code ""AP"". ","- Xellia’s Daptomycin is pharmaceutically equivalent to Sagent’s product (same active ingredient, strength, dosage form, and route).
- Both products lack bioequivalence demonstration; therefore, ""BX"" code is appropriate (i.e., insufficient data for therapeutic equivalence).
- Orange Book route of administration entry should be corrected for consistency.
- A TE Code is necessary for exemption or refund under PDUFA fees. ",6/1/2018,,2025-10-15,1.0,,,"The FDA has not reached a decision due to the need to address other agency priorities. The response was issued to comply with FDA regulations on citizen petitions, assuring the petitioner that a full response would be provided as soon as feasible given resource demands
",,no decision,2017,2870.0
fda-2017-p-6805,FDA-2017-P-6805-0001_Citizen_Petition_from_Bracco_Diagnostics_Inc.pdf,2017-12-08,False,original petition,Bracco Diagnostics Inc.,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.127(a)(6)(i)
- 21 C.F.R. § 314.430(a)
- 21 C.F.R. § 314.161(a)(1)",The agency’s potential acceptance or approval of ANDAs referencing the discontinued two-ingredient formulation of KINEVAC for injection.,"FDA should:
- Determine the two-ingredient KINEVAC formulation was withdrawn for safety and efficacy reasons.
- Conclude the old formulation is not a suitable RLD.
- Reject any ANDA referencing the discontinued KINEVAC formulation ","- The old two-ingredient formulation was unstable and prone to degradation, risking inaccurate diagnoses and unnecessary surgeries.
- The currently marketed formulation is significantly more stable and does not require overages.
- The older formulation had higher levels of impurities, posing safety concerns.
- Diagnostic standards (e.g., SNM guidelines for gallbladder function using GBEF) were established using the current formulation; using the older one could lead to false positives and improper surgeries.
- Continued use of the old formulation risks public health by undermining the safety and effectiveness of diagnostic procedures",5/31/2018,,2025-10-15,1.0,,,"The FDA stated that the petition raises complex issues requiring extensive review and analysis by agency officials. As such, they were unable to make a final decision at the time and issued this interim response per regulatory requirements
",,no decision,2017,2868.0
fda-2017-p-6967,FDA-2017-P-6967-0001_Citizen_Petition_from_Bergstrom_Nutrition_Redacted.pdf,2017-12-08,False,original petition,Natural Products Association (NPA) and Bergstrom Nutrition,advocacy/academic,"- Section 111.75(a)(1) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
",The petition addresses the FDA’s 100 percent identity testing requirement for dietary ingredients in dietary supplement manufacturing,"The petitioners request that the FDA exempt dietary supplement manufacturers using OptiMSM® (from Bergstrom Nutrition) from the 100 percent identity testing requirement for dietary ingredients
","- OptiMSM® is a well-characterized ingredient with a consistent identity profile produced under strict manufacturing controls.
- The petition argues that redundant testing imposes unnecessary regulatory burden and cost.
- Petitioners suggest that a robust supplier verification program and validated Certificates of Analysis (CoAs) should suffice to confirm identity.
- They highlight long-term use, product consistency, and quality assurance procedures in place at Bergstrom Nutrition.
- The exemption would help reduce testing requirements without compromising product quality or safety
",,,2025-10-15,0.0,,,,,no decision,2017,2868.0
fda-2017-p-7031,FDA-2017-P-7031-0001_Citizen_Petition_from_JRRapoza_Associates__Inc.pdf,2017-12-22,False,original petition,"JR Rapoza Associates, Inc.",industry/corporation,"- 21 CFR § 10.20
- 21 CFR § 10.30
- 21 CFR § 314.161
- 21 CFR § 25.31 (environmental exclusion)","The petition addresses the lack of a currently marketed Reference Standard (RS) drug product for Thiamine Hydrochloride Injection 100 mg/ml, NDA 0080556, which was discontinued but not for safety/efficacy reasons. It seeks a new RS designation in the Orange Book","The petitioner requests that the FDA designate a new Reference Standard (RS) drug in the Orange Book for Thiamine Hydrochloride Injection 100 mg/ml in a vial to enable submission of bioequivalent ANDAs
","- The original RS product (NDA 0080556 by Fresenius Kabi, USA, LLC) was discontinued for reasons other than safety or efficacy.
- Current FDA guidance allows for designation of a new RS for discontinued drugs.
- Other bioequivalent Thiamine Hydrochloride products are approved and could serve as RS.
- Availability of a designated RS will facilitate ANDA submissions for generic injectable products.
- The larger volume vial offers economic and dosing convenience benefits for healthcare providers",,,2025-10-15,0.0,,,,,no decision,2017,2854.0
fda-2017-p-7034,FDA-2017-P-7034-0001_Citizen_Petition_from_Jubilant_Generics_Limited.pdf,2017-12-19,False,original petition,Jubilant Generics Limited,industry/corporation,"- 21 U.S.C. § 355(j)(2)(C) (FDC Act)
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact exclusion)","FDA's approach to determining whether a drug product that differs in strength from an RLD (Valtrex®) can be considered suitable for an ANDA submission
","A formal determination by the FDA that Valacyclovir Hydrochloride Oral Tablet EQ 250 mg and 750 mg base is suitable for submission as an Abbreviated New Drug Application (ANDA)
","- Proposed strengths share same indication, dosage form, and route of administration as the RLD
- Strengths (250 mg & 750 mg) are reflected in RLD labeling
- No new safety/efficacy concerns
- Better palatability and dosing flexibility for pediatric and geriatric patients
- Current tablets (500 mg unscored, 1 g partially scored) do not allow individualized dosing
- No clinical trials needed due to established precedent and labeling data
- 250 mg strength already marketed in UK by GLAXOSMITHKLINE",,,2025-10-15,0.0,,,,,no decision,2017,2857.0
